Jump to Main Contents
NCCJ Hospital East

Home > Clinical depts > Department of Gastric Surgery

Department of Gastric Surgery

photo2026

Takahiro Kinoshita,  Masahiro Yura, Mitsumasa Yoshida, Daiki Terajima, Takayuki Tsuji, Ayumi Umemiya, and Koichiro Shimonaga, Mao Iino (as of April 2026)


Information

Surgery for International Patients

The Department of Gastric Surgery accepts and performs surgeries on stomach (gastric cancer) patients from overseas. We have accepted patients from many countries and have performed surgeries safely.

  1. All surgical procedures, including robotic surgery, are available.
  2. Even if the patient has received chemotherapy in his/her home country, we can perform the surgery if we have detailed information and determine that the patient is suitable for the surgery.
  3. If you are not covered by Japanese public insurance, you will be charged the actual cost of the surgery. Basically, we ask you to contact and go through a specialized medical intermediary agency.
  4. There is a hotel on the hospital grounds where your family can stay during your hospitalization.
  5. For a general gastrectomy, the hospital stay is approximately 10 days. After discharge, patients may stay at an adjacent hotel.

We have a lot of experience, especially in minimally invasive surgeries (MIS) such as robotic surgery, in which field, we have been a national and international leader. We are able to perform state-of-the-art robotic surgery on almost all patients, although the indication is determined by the individual patient's situation. The advantage of robotic surgery is that the surgeon can control the surgical instruments from the surgeon’s console, which are controlled by the anti-tremor function, allowing for more precise manipulation than conventional procedures (open or laparoscopic surgery). This reduces complications and speeds postoperative recovery. We also have extensive experience in performing function-preserving surgeries (avoiding total gastrectomy) using robotic surgery. Japan has long been a country with a high incidence of gastric cancer, and our extensive experience enables us to provide high-quality surgeries on a global scale.

 

For more information, please refer to the following page

International Patients

 

We provide high quality surgical treatment and treat patients from overseas with heartful hospitality, regardless of the region. We would be happy to hear from you if you wish to visit us.


Our Team and What We Do

Our department currently consists of seven surgeons. Our managing of tumors includes common gastric adenocarcinoma, adenocarcinoma of the esophagogastric junction (AEG: Siewert type II/III), and gastric submucosal tumors (GIST, etc.). Annually, more than 200 patients are operated on either by means of open surgery, laparoscopic or robotic surgery (Table 1). Laparoscopic gastrectomy with radical node dissection was introduced in 2010, and now our department is one of the leading institutions in Japan. Currently, more 99% of gastrectomy is performed under laparoscopy or by robot (Table 2). The basis of our surgery is radical extirpation of cancer lesions, but at the same time, organ functions and better quality of life (QOL) should be maintained. In addition, we strive to obtain better clinical outcomes for patients with diseases with dismal prognoses (type 4 gastric cancer or with progressive metastasis) by surgery combined with a modern chemotherapy regimen in cooperation with medical oncologists.

Table 1. Number of patients (in 2025)
Total 231(60)
Gastric Cancer (with neo adjuvant chemotherapy) 203(60)
GIST 21
Others 7
Table 2. Type of procedure (in 2025)
Robotic Surgery (with neo adjuvant chemotherapy) 124(50）
Distal Gastrectomy 71(22)
Pylorus-preserving Gastrectomy 0
Proximal Gastrectomy 36(21)
Total Gastrectomy 17(7)
Laparoscopic Gastrectomy (with neo adjuvant chemotherapy) 77(9)
Distal Gastrectomy 60(6)
Pylorus-preserving Gastrectomy 1(0)
Proximal Gastrectomy 13(2)
Total Gastrectomy 3(1)
Open Surgery (with neo adjuvant chemotherapy) 1(1)
Distal Gastrectomy 1(1)
Pylorus-preserving Gastrectomy 0
Proximal Gastrectomy 0
Total Gastrectomy 0

 



オペ写真

Usually 10-14 patients are hospitalized and six to eight patients undergo operations per week. A clinical conference of our division is held once a week to decide our treatment strategy. Further, a conference with internal medicine is held every week with doctors of Medical Oncology and Gastrointestinal Endoscopy, discussing the accurate diagnosis of the patients to decide the optimal treatment method. Laparoscopic (robot) surgery covers distal, proximal, pylorus-preserving, and total gastrectomy. D2 dissection can also be done, and its indication is expanding to locally advanced cancer or that after neo adjuvant chemotherapy (NAC). Recently, due to the progress of chemotherapy regimen, down-staging from cStageIV is sometimes seen. For such patients, we selectively perform conversion surgery to achieve favorable outcomes. For AEGs, the transhiatal approach or thoraco-laparoscopic Ivor-Lewis surgery can be done by minimal invasive means.

 

Research Activities & Clinical Trials

We aggressively publish our clinical research data in domestic or international congresses. In addition, we participate in multi-institutional clinical trials conducted by the Japan Clinical Oncology Group (JCOG) – Gastric Surgery Study Group or other international and domestic organizations, and work as PI for some clinical trials (JCOG1809) (COSMOS-GC regarding liquid biopsy). We started a research of auto intelligence technology relevant with laparoscopic or robot-assisted surgery.

Ongoing Trials as a Principal Investigator

1) JCOG1809 Single-arm phase II trial to evaluate safety of Laparoscopic Total Gastrectomy with Spleen-PReservING splenic hilar dissection for proximal gastric cancer invading the greater curvature (LTG-SPRING-PII)

2) Multi-institutional collaborative study aiming to elucidate the spatiotemporal molecular profiles for patients with malignant tumor (SCRUM-Japan MONSTER-SCREEN-3)

3)Conquer Solid Malignancies by blood screening –gastric cancer- 01 (COSMOS-GC)

4) EPOC2301 An open label phase 2 study of Total Neoadjuvant Therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (pemflot-tnt study)

 

Ongoing Trials as a Co-Investigator

1) JCOG1509 Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer (NAGISA trial)

2) JCOG1711 Randomised controlled phase III trial to evaluate Omentum preserving gastrectomy for patients with ADvanced Gastric Cancer　(ROAD-GC)

3) JCOG1907 Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-2N0-2 Gastric Cancer patients (MONA-LISA Study)

4) An open label phase 2 study to evaluate the safety and efficacy of lenvatinib with pembrolizumab in the neoadjuvant / adjuvant treatment for patients with gastric cancer (EPOC2001)

5) An open label phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003)

6) JCOG2204 A randomized phase II study to compare the pathological responses of neoadjuvant chemotherapy for type 4 or large type 3 gastric cancer: 5-FU, Oxaliplatin and Docetaxel (FLOT) versus Docetaxel, Oxaliplatin and S-1(DOS)

7) Additional TR study on "Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma" (T-DXd_NAC TR)

8) An Open label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the neoadjuvant / adjuvant treatment for Patients with Gastric Cancer

9) A case-control clinical evaluation of the Exact Sciences Multi-Cancer Early Detection(MCED) in Japan (CRANE Study)

10) Construction of surgical database for the tacit knowledge of surgeons (S-access Japan Project)

11) Multiomics data cancer diagnostics therapies (TITANIA Study)

12) Development of a Clinical Decision Support System (CDSS) with Artificial Intelligence for Gastric and Esophageal Adenocarcinomas (AIM Study)

13)The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for gastric cancer

14) The UGIRA International Registry for Robot-Assisted Minimally Invasive Esophagectomy (RAMIE)

Observership Visits for International Doctors

We always welcome doctors from overseas to share our expertise with the international gastric surgical oncology community. Since 2014, we have hosted more than 130 observership visitors from 20 countries and regions.

Usually, the observership period is from a few days to 90 days, up to your request.

For more information, please refer to our website for the observership visit

  • internationaldoctors2026

     

  • with_Pietro.jpg

Future prospects

We will keep striving to obtain better survival outcomes for the patients with far advanced diseases; for multidisciplinary therapy (chemotherapy, molecular-target agents or immune check-point inhibitor), collaborating with medical oncologists is essential. Additionally, we will continue to develop less-invasive as well as high-quality surgical methods (laparoscopic or robotic surgery), to improve patients' QOL and realize complete cures. It is also our obligation to expand our knowledge and experience globally as one of the main countries in terms of gastric cancer occurrence.

Latest journals

  1. Yasufuku I, Kinoshita T, Bando E, Kurokawa Y, Fujisaki M, Ojima H, Arigami T, Fujibayashi S, Watanabe M, Furukawa K, Matsuhashi N, Terashima M. Correction: Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study. Gastric Cancer. 2026 Jan;29(1):191. doi: 10.1007/s10120-025-01709-4. Erratum for: Gastric Cancer. 2026 Jan;29(1):177-190. doi: 10.1007/s10120-025-01683-x. PMID: 41533052.
  2. Neves-Marques C, Abulazayem M, Wong GYM, Maldonado RD, Viswanath Y, Boddy A, Donohoe C, Scarano JP, Martinino A, Aamery A, Abdulkhakimov N, Abuobaida EE, Aday U, Al-Shami K, Alhajami F, Almeida A, Almoshantaf MB, Ahmed H, Andrada M, Anwer AW, Awad AK, Baili E, Baraket O, Barbosa J, Baker C, Bakri A, Boras Z, Caiado A, Cayirci C, Calini G, Cianci P, Cinal E, Chouliaras C, Colak E, Correia MT, Costeira B, Davletshina V, D'Acapito F, Donmez T, Drozdov E, Ercolani G, Erdene S, Erginöz E, Ferreira SR, Fragoso M, Framarini M, Galandarova A, Genser L, Gorohov I, Grosek J, Guerrero S, Hasırcı I, Ibrahimli A, Ithurralde-Argerich J, Karabulut M, Kinoshita T, Khalid IB, Khan K, Khattak S, Khomyakov V, Krawczyk W, Khamees A, Kostrygin A, Košir J, Lorenc Z, Milhomem J, Marom G, Melo A, Menasria A, Meric S, Mulita F, Muratore A, Omarov T, Palomba G, Paul N, Pathak A, Pavone G, Pavlov R, Pinillla R, Rasheed O, Remini A, Ryabov A, Samadov E, Samarasam I, Sandag E, Santos J, Sanchez E, Saroglu A, Schizas D, Serralheiro PA, Simsek O, Sobolev D, Souadka A, de Sousa JV, Sousa F, Suer M, Surendran S, Syllaios A, Syed AA, Terajima D, Tokocin M, Triantafyllou T, Uludağ S, Uprak T, Vaz S, Vecchiato M, Verras GI, Veroux M, Voon K, Vovin K, Yacob M, Walędziak M, Zacharenko A, Zahara FT, Singhal R, Mahawar K; HOLD Study Collaborative Group. Stomach cancer elective surgery morbidity and mortality at 90-Day (Hold Study): a prospective, international collaborative cohort study. Langenbecks Arch Surg. 2025 Nov 14;411(1):12. doi: 10.1007/s00423-025-03890-7. PMID: 41236666; PMCID: PMC12618408.
  3. Habu T, Ushiyama S, Nakayama I, Yura M, Yoshida M, Sakamoto N, Kuwata T, Shitara K, Kinoshita T. Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy? Ann Surg Oncol. 2025 Oct 30. doi: 10.1245/s10434-025-18641-7. Epub ahead of print. PMID: 41168607.
  4. Kinoshita T, Yura M, Yoshida M, Terajima D. Is Laparoscopic/Robotic Total Gastrectomy a Reasonable and Adequate Treatment for Proximal Advanced Gastric Cancer? Ann Gastroenterol Surg. 2025 Aug 23;10(1):42-53. doi: 10.1002/ags3.70081.
  5. Ikeda J, Takeuchi M, Kawakubo H, Yura M, Kinoshita T, Morito A, Nunobe S, Morimoto Y, Egawa T, Furube T, Maeda Y, Matsuda S, Kitagawa Y. Assessment of AI-driven anatomical recognition in robotic gastrectomy: A multicenter retrospective analysis. Surg Endosc. 2025 Dec;39(12):8349-8356. doi: 10.1007/s00464-025-12248-5. Epub 2025 Sep 26. PMID: 41003776.
  6. Strong JS, Yura M, Takeuchi M, Kawakubo H, Furube T, Maeda Y, Matsuda S, Kinoshita T, Kitagawa Y. External Validation of an Automated Surgical Step Recognition Model for Robotic Distal Gastrectomy (RDG) Using a Multicenter Dataset. Ann Gastroenterol Surg. 2025 May 20;9(6):1155-1162. doi: 10.1002/ags3.70042. PMID: 41199976; PMCID: PMC12586924.
  7. Nagata H, Kinoshita T, Komatsu M, Habu T, Yoshida M, Yura M. Comparison of partially extracorporeal versus totally intracorporeal Roux-en-Y reconstruction in robotic surgery for gastric cancer. Surg Endosc. 2025 Dec;39(12):8080-8088. doi: 10.1007/s00464-025-12171-9. Epub 2025 Sep 13. PMID: 40944741.
  8. Nagata H, Kinoshita T, Komatsu M, Habu T, Yoshida M, Yura M. Outcomes of Laparoscopic Distal Gastrectomy for Gastric Cancer by Female and Male Resident Surgeons. Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70135. doi: 10.1111/ases.70135. PMID: 40854572.
  9. Terajima D, Kojima M, Sakashita S, Taki T, Kinoshita T, Ishii G, Sakamoto N. Evaluating peritoneal elastic laminal invasion to improve stratification of patients with pT3 gastric cancer. Gastric Cancer. 2025 Sep;28(5):862-871. doi: 10.1007/s10120-025-01627-5. Epub 2025 Jul 24. PMID: 40705176.
  10. Jubashi A, Nakayama I, Sakamoto N, Takei S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Kuwata T, Sato K, Fujita T, Yoshida M, Yura M, Kinoshita T, Shitara K. Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors. JCO Precis Oncol. 2025 Aug;9:e2400925. doi: 10.1200/PO-24-00925. Epub 2025 Aug 1. PMID: 40749150; PMCID: PMC12316131.
  11. Choi S, Kinoshita T, Obama K, Sakurai K, Kubo N, Ikoma N, Guner A, Kim HI. Impact of articulating laparoscopic instrument-assisted gastrectomy with D2 lymphadenectomy on perioperative and oncologic outcomes compared with conventional laparoscopy: a propensity score matching analysis. Surg Endosc. 2025 Sep;39(9):5596-5603. doi: 10.1007/s00464-025-11976-y. Epub 2025 Jul 10.
  12. Hisaoka K, Matsuda S, Kawakubo H, Takeuchi M, Wada T, Sekine S, Takamoto T, Tsutsui M, Yura M, Ishida H, Ono Y, Kamiya S, Bando E, Nunobe S, Kinoshita T, Kitagawa Y. Distribution of Lymph Node Metastasis and Prognosis in Duodenal Bulb Tumors: A Multicenter Retrospective Study. Ann Surg Oncol. 2025 Sep;32(9):6492-6500. doi: 10.1245/s10434-025-17388-5. Epub 2025 May 8. PMID: 40338425.
  13. Stroobant EE, Kong SH, Bencivenga M, Kinoshita T, Kim TH, Sano T, de Manzoni G, Yang HK, Kitagawa Y, Strong VE. Korea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different? Gastric Cancer. 2025 Jul;28(4):559-568. doi: 10.1007/s10120-025-01613-x. Epub 2025 Apr 16. PMID: 40240698.
  14. Harada K, Sakamoto N, Kitaoka T, Nakamura Y, Kondo R., Morisue R, Hashimoto H, Yamamoto Y, Ukai S, Maruyama R, Sakashita S, Kojima M, Tanabe K, Ohdan H, Shitara K, Kinoshita T, Ishii G, Yasui W, Ochiai A, Ishikawa S. PI3 expression predicts recurrence after chemotherapy withDNA-damaging drugs in gastric cancer. J Pathol. 2025 Apr;265(4):472-485. doi: 10.1002/path.6400. Epub 2025 Feb 20.
  15. Amini N, Kinoshita T, Arrieta M, Yoshida M, Nagata H, Habu T, Komatsu M, Yura M. Novel Robotic Valvuloplastic Esophagogastrostomy Technique After Proximal Gastrectomy: A Safety and Feasibility Study. Surg Laparosc Endosc Percutan Tech. 2025 Apr 1;35(2):e1322. doi: 10.1097/SLE.0000000000001322.
  16. Nagata H, Kinoshita T, Sakashita S, Kojima M, Taki T, Kuwata T, Yura M, Shitara K, Ishii G, Sakamoto N. Area of Residual Tumor Measurement After Preoperative Chemotherapy as an Objective and Quantitative Method for Predicting the Prognosis of Gastric Cancer: A Single‐Center Retrospective Study. World J Surg. 2025 Mar;49(3):717-726. doi: 10.1002/wjs.12482. Epub 2025 Jan 14.
  17. Kooij CD, de Jongh C, Kingma BF, van Berge Henegouwen MI, Gisbertz SS, Chao YK, Chiu PW, Rouanet P, Mourregot A, Immanuel A, Mala T, van Boxel GI, Carter NC, Li H, Fuchs HF, Bruns CJ, Giacopuzzi S, Kalff JC, Hölzen JP, Juratli MA, Benedix F, Lorenz E, Egberts JH, Haveman JW, van Etten B, Müller BP, Grimminger PP, Berlth F, Piessen G, van den Berg JW, Milone M, Luketich JD, Sarkaria IS, Sallum RAA, van Det MJ, Kouwenhoven EA, Brüwer M, Harustiak T, Kinoshita T, Fujita T, Daiko H, Li Z, Ruurda JP, van Hillegersberg R; UGIRA Study Group. The Current State of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE): Outcomes from the Upper GI International Robotic Association (UGIRA) Esophageal Registry. Ann Surg Oncol. 2025 Jun;32(2):892-893
  18. Tomi Y, Kinoshita T, Yura M, Sakamoto N, Fujita T, Tokunaga M, Kinugasa Y. Accuracy of preoperative estimation of esophageal invasion length in adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement. Surg Today. 2024 Nov 5. doi: 10.1007/s00595-024-02955-2. Online ahead of print.
  19. Minakata N, Kadota T, Sakashita S, Inaba A, Sunakawa H, Takashima K, Nakajo K, Murano T, Shinmura K, Yoda Y, Ikematsu H, Fujita T, Kinoshita T, Yano T. Tumour thickness is associated with metastasis in submucosal invasive adenocarcinoma of the esophagogastric junction. Dis Esophagus. 2024 Nov 28;37(12):doae083. doi: 10.1093/dote/doae083.
  20. Nagata H, Kinoshita T. Komatsu M, Habu T, Yoshida M, Yura M. Comparison of robotic versus laparoscopic total gastrectomy for gastric cancer: a single-center retrospective cohort study in a Japanese high-volume center. Eur J Surg Oncol. 2024 Dec;50(12):108706. doi: 10.1016/j.ejso.2024.108706. Epub 2024 Sep 28.
  21. Arrieta GM, Kinoshita T, Amini N, Akimoto E, Yura M, Yoshida M, Habu T, Nagata H, Komatsu M, Sano J, Terajima D. Oncological long-term outcomes of laparoscopic versus open gastrectomy for cT3-4 gastric cancer at surgical staging: a propensity-score matched cohort study. Surg Endosc. 2024 Nov;38(11):6682-6690. doi: 10.1007/s00464-024-11287-8. Epub 2024 Sep 25.
  22. Okazaki U, Nakayama I, Sakamoto N, Kuwata T, Kawazoe A, Yoshida M, Yura M, Matsubara Y, Jubashi A, Sato S, Ushiyama S, Miyashita Y, Kobayashi A, Hashimoto T, Mishima S, Kotani D, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Kinoshita T, Shitara K. Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience. ESMO Gastrointestinal Oncology. 2024 Sep. Online Published. doi: 10.1016/j.esmogo.2024.100086
  23. Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D, Nakamura M, Hojo H, Sakashita S, Kinoshita T, Yano T, Mitsunaga S, Nishikawa H, Koyama S, Kojima T. Definitive chemoradiotherapy induce T-cell inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.. J Gastroenterol. 2024 Sep;59(9):798-811
  24. Kitaoka T, Harada K, Sakashita S, Kojima M, Taki T, Kuwata T, Kinoshita T, Futakuchi M, Ishii G, Sakamoto N. Quantification of Gremlin 1 throughout the tumor stroma using whole slide imaging and its clinicopathological significance in gastric cancer. Virchows Arch2024 Dec;485(6):1107-1116. doi: 10.1007/s00428-024-03903-8. Epub 2024 Sep 3.
  25. Yoshida M, Kitaguchi D, Takeshita N, Matsuzaki H, Ishikawa Y, Yura M, Akimoto T, Kinoshita T, Ito M. Surgical step recognition in laparoscopic distal gastrectomy using artificial intelligence: a proof-of-concept study. Langenbecks Arch Surg. 2024 Jul 12;409(1):213. doi: 10.1007/s00423-024-03411-y.
  26. Takei S, Kawazoe A, Jubashi A, Komatsu M, Sato K, Mishima S, Kotani D, Yura M, Sakamoto N, Sakashita S, Kuwata T, Kojima T, Fujita T, Kinoshita T & Shitara K. Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: A single-institution experience. ESMO Gastrointestinal Oncology. 2024 Apr. Online Published. doi: 10.1016/j.esmogo.2024.100050
  27. Akimoto E, Kinoshita T, Yura M, Yoshida M, Okayama T, Habu T, Komatsu M, Nagata H, Terajima D. Feasibility of laparoscopic/robot‑assisted surgery for Borrmann type 4 gastric cancer: a comparison study with conventional open surgery. Surg Endosc. 2024 Jun;38(6):3337-3345
  28. Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, Sekine S and Hiraoka N. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer. Br J Cancer Reports. 2024 Mar;2(1):18
  29. Cas dJ, Cianchi F, Kinoshita T, Kingma F, Piccoli M, Dubecz A, Kouwenhoven E, Det Mv, Mala T, Coratti A, Ubiali P, Turner P, Kish P, Borghi F, Immanuel A, Nilsson M, Rouvelas PI, Hӧlzen JP, Rouanet P, Saint-Marc O, Dussart D, Patriti A, Bazzocchi F, Etten Bv, Haveman JW, DePrizio M, Sabino F, Viola M, Berlth F, Grimminger PP, Roviello F, Hillegersberg Rv, Ruurda J; UGIRA Collaborative Group. Surgical Techniques and Related Perioperative Outcomes After Robot-assisted Minimally Invasive Gastrectomy (RAMIG):Results From the Prospective Multicenter International Ugira Gastric Registry. Ann Surg. 2024 Jul;280(1):98-107
  30. Uyama I, Shibasaki S, Inaki N, Ehara K, Oshiro T, Okabe H, Obama K, Kasama K, Kinoshita T, Kurokawa Y, Kojima K, Shiraishi N, Suda K, Takiguchi S, Tokunaga M, Naitoh T, Nagai E, Nishizaki M, Nunobe S, Fukunaga T, Hosoda K, Sano T, Sagawa H, Shindo K, Nakagawa M, Hiratsuka T. Practice guidelines on endoscopic surgery for qualifiedsurgeons by the endoscopic surgical skill qualificationsystem: Stomach. Asian J Endosc Surg. 2024 Jan;17(4):e13365.
  31. Kunisaki C, Katai H, Sakuramoto S, Mizusawa J, Katayama H, Kadoya S, Yamada T, Kinoshita T, Yoshikawa T, Terashima M on behalf of the Stomach Cancer Study Group of Japan Clinical Oncology Group. A Nonrandomized Controlled Trial Long-term outcomes of LATG/LAPG for cStage I gastric cancer: JCOG1401. Gastric Cancer. 2024 Jan;27(1):164-175
  32. Komatsu M, Kitaguchi D, Yura M, Takeshita N, Yoshida M, Yamaguchi M, Kondo H, Kinoshita T, Ito M. Automatic surgical phase recognition-based skill assessment in laparoscopic distal gastrectomy using multicenter videos. Gastric Cancer. 2024 Jan;27(1):187-196
  33. Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, Watanabe M, Imamura H, Kinoshita T, Yasuda T, Hihara J, Fukuda H, Yoshikawa T, Boku N, Terashima M. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024 Jan;27(1):580-589
  34. Honda M, Ri M, Kinoshita T, Kawakubo H, Aizawa M, Bamba T, Matsuda S, Kawamura H, Yoshida M, Nunobe S. Comparison of the survival outcomes between retro-colic and ante-colic Roux-en-Y reconstruction after gastrectomy for gastric cancer. Ann Gastroenterol Surg. 2024 Feb;8(3):443-449.
  35. Makuuchi R, Terashima M, Terada M, Mizusawa J, Kita R, Tokunaga M, Omori T, Ojima T, Ehara K, Watanabe M, Yanagimoto Y, Nunobe S, Kinoshita T, Ito S, Nishida Y, Hihara J, Boku N, Kurokawa Y, Yoshikawa T, the Stomach Cancer Study Group of Japan Clinical Oncology Group. Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): A study protocol. BMC Cancer. 17 October 2023. Published Online. https://doi.org/10.1186/s12885-023-11481-2
  36. Mitsui T, Mori A, Takamatsu T, Kadota T, Sato K, Fukushima R, Okubo K, Umezawa M, Takemura H, Yokota H, Kuwata T, Kinoshita T, Ikematsu H, Yano T, Maeda S, and Soga K. Evaluating the identification of the extent of gastric cancer by over-1000 nm near-infrared hyperspectral imaging using surgical specimens. J. Biomed. Opt. 22 August 2023, Published Online. doi:10.1117/1.JBO.28.8.086001
  37. Komatsu M, Kinoshita T, Akimoto E, Yoshida M, Nagata H, Habu T, Okayama T, Yura M. Advantages of robotic gastrectomy for overweight patients with gastric cancer: a comparison study of robotic gastrectomy and conventional laparoscopic gastrectomy. Surg Today. 2023 Nov;53(11):1260-1268. doi: 10.1007/s00595-023-02681-1. Epub 2023 Apr 6.
  38. Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee SW, Yoshida K, Koeda K, Hiki N, Kunisaki C, Tokunaga M, Otsubo D, Takagane A, Misawa K, Kinoshita T, Cho H, Doki Y, Nunobe S, Shiraishi N, Kitano S; for the Japanese Laparoscopic Surgery Study Group (JLSSG). Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer The JLSSG0901 Randomized Clinical Trial. JAMA Surg. 2023;158(5):445-454
  39. Akimoto E, Kuwata T, Shitara K, Kawazoe A, Sakamoto N, Ishii G, Ochiai A, and Kinoshita T. The impact of programmed death-ligand 1 expression on mismatch repair deficiency and Epstein-Barr virus status on survival outcomes in patients with stage II/III gastric cancer after surgery. Ann Surg Oncol. 2023;30(8):5227-5236
  40. Habu T, Kumanishi R, Ogata T, Fujisawa T, Mishima S, Kotani D, Kadowaki S, Nakamura M, Hojo H, Fujiwara H, Kumagai S, Koyama S, Fujita T, Kinoshita T, Nishikawa H, Yano T, Tajika M, Muro K, Mitsunaga S, Kojima T & Bando H. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. Esophagus. 2023;20(3)8時53分3-540
  41. Sakashita S. Sakamoto N, Kojima M, Taki T, Miyazaki S, Minakata N, Sasabe M, Kinoshita T, Ishii G & Ochiai A. Requirement of image standardization for AI-based macroscopic diagnosis for surgical specimens of gastric cancer. Journal of Cancer Research and Clinical Oncology. 2023;149(9):6467-6477
  42. Yamaguchi T, Takashima A, Nagashima K, Kumagai K, Yamada T, Terashima M, Yabusaki H, Nishikawa K, Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukagawa T, Kinoshita T, Watanabe M, Ishiyama K, Inoue K & Boku N. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study. Gastric Cancer. 2023;26(2):307-316.
  43. Mizusawa J, Tokunaga M, Machida N,Yabusaki H, Kawabata R, Imamura H, Kinoshita T, Nomura T, Nunobe S, Tsuji K, Katayama H, Fukuda H, Boku N,Yoshikawa T, Terashima M and Stomach Cancer Study Group of the Japan Clinical Oncology Group. Protocol digest of a phase III trial to evaluate the efficacy of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA Trial). Jpn J Clin Oncol. 2023;53(2):168-173.
  44. Kinoshita T, Komatsu M. Artificial intelligence in surgery and its potential for gastric cancer. J Gastric Cancer. 2023;23(3):400-409.
  45. Kinoshita T, Akimoto E, Yura M, Yoshida M. Survival outcomes of laparoscopic versus open total gastrectomy with nodal dissection for gastric cancer in a high-volume Japanese center: A propensity score-matched analysis. Ann Gastroenterol Surg. 2023;7(1):53-62.
  46. Komatsu M, Kinoshita T, Akimoto E, Yoshida M, Terajima D, Nagat H, Habu T, Okayama T, Takabe Y, Harada J, Yamaguchi M, Yura M. The Significance of Staging Laparoscopy in Detection of Radiologically Occult Peritoneal Carcinomatosis in Gastric Cancer With Gastric Outlet Obstruction: Consideration of The Optimal Treatment Approach. Anticancer Research. 2022;42(11):5571-5578.
  47. Akimoto E, Kinoshita T, Sato R, Yura M, Harada J, Yoshida M, Okayama T, Takabe Y, Tanaka Y, Tomi Y, Habu T. Impact of postoperative intra‑abdominal infectious complications on survival outcomes in patients with gastric cancer who underwent laparoscopic surgery. Surg Endosc. 2023;37(1):382-390.
  48. Kanda M, Terashima M, Kinoshita T, Yabusaki H, Tokunaga M, Kodera Y. A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer. Gastric Cancer. 2023;26(1):108-115
  49. Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodea Y. A multicenter, open‑label, single‑arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer. 2022;25(3):619-628.
  50. Shogo Kumagai, Koyama S, Itahashi K, Tanegashima T, Lin YTTogashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe  G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno  Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T,Mori T,Yamazaki N, Tsuboi M,YatabeY, Kinoshita T, Doi T,Shitara K, Mano H, Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201-218.
     

    Please search our other publications here